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Abstract Rapid uptake previously demonstrated by intradermal
(ID) drug administration indicates compound delivery within the
dermis may have clinical and pharmacological advantages for
certain drug therapies. This study is the first clinical trial to eval-
uate continuous microneedle-based drug infusion, device wear-
ability, and intradermal microneedle insulin kinetics over a multi-
day (72 h) wear period. This was a single center, open-label, two-
period crossover study in T1DM patients on continuous subcu-
taneous insulin infusion (CSII). Patients received treatment dur-
ing interventional visits: one SC and one ID basal/bolus infusion
of insulin aspart (NovoRapid® U-100) administered over 3 days
in a randomized order. Twenty-eight patients were randomized
and exposed to trial product, and 23 completed the study. Bolus
insulin infusions were given prior to standardized breakfast and
lunch test meals on each of the three treatment days. Blood
samples were drawn at predefined time points for measurements
of insulin aspart and blood glucose in serum. The primary end-
point insulin Tmax demonstrated that ID bolus infusion was
associated with a significantly shorter Tmax with statistically
significantly smaller intra-subject variability, compared to SC
infusion, and this difference was maintained over three treatment
days. Analyses of secondary PK endpoints corresponded with
the primary endpoint findings. Postprandial glycemic response
was significantly less pronounced after ID bolus: For most end-
points ID vs. SC, differences were statistically significant within
the 0–1.5 or 0–2 h time period. Intradermal delivery of insulin is
a viable delivery route alternative providing reduced time for
insulin absorption with less intra-subject variability and lower
glycemic response.
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Introduction
Faster insulin action to mimic pancreatic response to blood glu-
cose (BG) is a fundamental challenge for improved glycemic
control in diabetes patients. Postprandial glycemic excursions
in healthy individuals are believed to be small (i.e., in the range
of 20–50 mg/dL above baseline glycemia) and return to normal
range within 2 h despite consuming considerable amounts of
carbohydrates with meals [1, 2]. In order to mimic the physio-
logic rapid increase in insulinemia, which also rapidly decreases
hepatic glucose production [3], rapid-acting insulin analogs have
been developed [4]. Current rapid-acting insulin analogs have
faster subcutaneous (SC) kinetics than regular insulin, but do
not replicate the normal pancreatic insulin secretion [5]. Delayed
and unpredictable insulin uptake creates challenges formanaging
postprandial glycemic excursions and establishing predictive
control for closed-loop insulin delivery systems.
Traditional SC injection or infusion delivers insulin into the
subcutaneous adipose tissue, from which it is absorbed into the
bloodstream. Continuous subcutaneous insulin infusion (CSII) is
an effective therapy to minimize hypoglycemia and maintain
long-term glycemic control in type I diabetes patients. Pump
therapy use is expanding among type 1 diabetes patients as
new and improved pump technologies emerge. With the
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recognition that pump therapy will be an enabling part of a
closed-loop artificial pancreas system, all components of the de-
livery system, including the pump and infusion set, must be
critically evaluated, validated, and optimized for delivery in order
to maintain the appropriate and anticipated insulin dosing sched-
ule for maintenance of blood glucose within a normal range.
Within this context, researchers are continually investigating
the efficacy, safety, and patient acceptability for alternative for-
mulations [6, 7], devices [8], and routes of insulin delivery (oral
[9], transdermal [10], inhaled [11], intra-nasal [12], and intrader-
mal [13, 14]) in efforts to enhance glycemic control.
There is no standardized definition or dimensional specifi-
cation for microneedles, and various systems have been uti-
lized for targeted administration to the epidermal and dermal
tissue layers as a means to bypass the physical and chemical
transport barriers imposed by the stratum corneum. A variety
of fabrication techniques, designs, materials, and usage
methods have been employed to create diverse devices
including solid microneedles to enhance passive epidermal
transport, coated or dissolvable solid microneedles for in
situ dissolution, and hollow microneedles for direct fluid
transport to the dermis [15, 16]. In this study, a single
hollow stainless steel microneedle (34 G×1.5 mm length;
178 and 63.5 µm nominal outer and inner diameters) was
utilized for direct administration of clinically meaningful
basal and bolus insulin doses to the dermal tissue bed
over a 3-day infusion period (Fig. 1a, b). The device
incorporated traditional design and functional aspects of
commercial SC infusion sets including application method
and tubing line connections for commercial CSII pumps.
The microneedle catheter set used herein has been exten-
sively characterized in preclinical [17] and clinical studies
to ensure consistent and effective intradermal administra-
tion for insulin and other drugs [18, 19].
Intradermal (ID) injections are used clinically for the deliv-
ery of some vaccines such as flu, rabies, cholera, and Bacille
Calmette-Guérin (BCG) for tuberculosis, some local medica-
tions, such as lidocaine for local anesthesia, lymph node stag-
ing [20], and some diagnostic tests, such as the Mantoux test
to assess immune status against tuberculosis [13]. However,
delivery of drug substances, such as insulin, into the dermis is
not routine. Rapid systemic uptake and increased bioavailabil-
ity have been previously demonstrated in preclinical animal
models using single hollow stainless steel microneedles for ID
delivery of protein therapeutics [17], indicating that delivery
of compounds within the dermis may have clinical and phar-
macological advantages for certain drug therapies [21]. A po-
tential rationale for these altered pharmacokinetic effects in-
clude enhanced vascular uptake from dense dermal capillary
beds. Alternatively, human clinical studies indicate that rapid
uptake may be driven by a lymphatic mechanism that trans-
ports insulin from the skin administration site via draining
lymph vessels and into the systemic circulation [13].
Previously reported clinical studies have demonstrated vi-
able ID microneedle delivery up to 24 h with placebo solu-
tions [22], continuous ID basal insulin infusion for up to 6 h
[18, 19], and faster insulin action from bolus ID insulin lispro
delivery compared to the standard subcutaneous route
[23–27]. This study is the first clinical trial to evaluate contin-
uous microneedle-based drug infusion including both basal
and bolus administration, device wearability, and intradermal
microneedle insulin kinetics over a multi-day (72 h) wear




Male and female type 1 diabetes mellitus (T1DM) patients in
general good health on insulin pump therapy with carbohy-
drate counting for at least 6 months, aged 18 to 55 years, with
BMI≤32 kg/m2, with HbA1c≤8.0 %, using ≤60 U of insulin
on a typical day, and negative tests for hepatitis B/C and HIV
at screening, were eligible for participation in the study. Ex-
clusion criteria included conditions that could interfere with
insulin absorption (lipodystrophy), distribution (impaired car-
diac function, uncontrolled hypertension), clearance
(gastroparesis, impaired hepatic, or renal functions), and other
concomitant interfering medications or conditions as judged
by the investigator.
Study design and procedures
This was a single center, open-label, two-period crossover
study, randomized by infusion order, in T1DM patients on
continuous subcutaneous insulin infusion (CSII). The pro-
tocol was approved by an independent ethics committee
(Ethikkommission der Ärztekammer Nordrhein, Düsseldorf,
Germany), appropriate regulatory bodies (German Federal
Institute for Drugs and Medical Devices (BfArM)), and
conducted in compliance with good clinical practice
(GCP), the Declaration of Helsinki, and applicable regula-
tory requirements.
The study was completed over a multi-week period
consisting of three study visits: a screening visit (V1) and
two interventional visits (V2 and V3). After establishing
eligibility and enrollment, patients received treatment during
two interventional visits: one SC and one ID basal/bolus
infusion of insulin aspart (NovoRapid® U-100, Novo
Nordisk, Copenhagen, Denmark) administered over 3 days
in a randomized order.
For each dosing visit, patients arrived the evening prior to
the first standardized meal to verify compliance with protocol
criteria. An intravenous catheter was inserted into a peripheral
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vein of the arm for manual blood sampling. Infusion sets, ID
(34 G×1.5 mm length stainless steel microneedle catheter set,
BD Technologies, Research Triangle Park, NC) or SC (25 G×
6 mm length soft cannula, Quick-Set, Medtronic Minimed,
Northridge, CA), were connected to an insulin infusion pump
(Animas® Vibe™, Animas Corporation, West Chester, PA)
and primed according to the manufacturer’s instructions. Sets
were placed into the patient’s abdomen (periumbilical, left or
right) using a customized applicator for the ID set, or the
manufacturer recommended inserter for the SC set (custom-
ized Sof-serter® and Quick-serter® respectively, both
Medtronic Minimed, Northridge, CA). Due to the small adhe-
sive surface on the microneedle catheter, a modified IV dress-
ing (IV3000 1-Hand, Smith & Nephew, England) was used
for additional securement over the catheter. A safety loop was
used on all catheter lines as recommended by general insulin
pump user guidance (Fig. 1c). The respective infusion sets
provided all basal and bolus insulin delivery of insulin
aspart for the duration of each 72-h study period. A fluid
pressure transducer (BD-DTX™ Plus, Becton Dickinson,
Franklin Lakes, NJ) was connected in-line between the
pump reservoir and each infusion set to monitor infusion
delivery pressure, with automated data capture via a commer-
cial data logging system (LORDMicroStrain®, Williston, VT)
to provide a secondary post hoc measure of delivery status. The
pump/pressure monitoring system combination was contained
in a waist pack for the duration of delivery due to its potentially
cumbersome size.
Individual meal bolus doses were determined based on
patient self-reported insulin to carbohydrate ratios and insulin
sensitivity, historical self-reported insulin usage for meal cov-
erage, and clinician review and adjustment of insulin usage
during the in-clinic BG stabilization period the evening prior
to the first morning meal. Basal insulin infusion rates were
initiated based on the patient’s known daily delivery profile
and could be adjusted by the clinician to maintain levels with-
in 70–160 mg/dL according to a predetermined sliding scale
and hourly changes in glycemia. A continuous glucose mon-
itor (Seven Plus®, DexCom Inc., San Diego, CA) calibrated
per manufacturer’s recommendations was applied to continu-
ously monitor glycemia as a safety measure, in addition to
periodic blood sampling for BG determination.
After maintaining targeted blood glucose range during the
preceding night, bolus insulin doses were administered via the
respective infusion catheter prior to standardized breakfast
and lunch test meals on each of the three treatment days. Each
meal insulin bolus was calculated based on the patient’s insu-













Fig. 1 a Investigational microneedle infusion set with a 34G×1.5 mm
stainless steel microneedle (left) compared to a standard 25G×6 mm
polymer cannula on a commercial CSII set. b Investigational
intradermal microneedle catheter set showing components: 1.5-mm
microneedle, fluid tubing line, skin adhesive, and Luer connector for
joining to insulin infusion pumps. c ID microneedle catheter with
IV3000 overtape on a patient’s abdomen (a) showing tubing safety
loops (b), CGM for BG safety monitoring (c), insulin pump (d), in-line
pressure transducer (e), and infusion pressure monitoring hardware ( f )
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scale then delivered immediately prior to breakfast (t=0 min)
and lunch (t=360 min) consumption. Breakfast was a high
glycemic index (60 g carbohydrates) solid meal, and lunch
was a mixed meal based on the individual’s calculated daily
energy intake and equivalent in caloric composition by day.
Breakfast and lunch meals were consumed within 15 min
followed by serial blood sampling with BG monitoring for a
period of 6 and 4 h, respectively. Patients were asked to re-
main sedentary for 2 h after meals. Identical study procedures
were utilized for the remaining dosing visit days (Fig. 2).
PK/PD assessments
To assess insulin absorption kinetics and glycemic response,
blood samples for measurements of insulin aspart and blood
glucose in serum were drawn at predefined time points
throughout dosing visits. Serial samples for safety BG deter-
mination, but not PK analysis, were obtained at a minimum
every 2 h. Meal PK/PD analysis samples were acquired im-
mediately pre-bolus and for 4–6 h post-bolus for breakfast and
lunch meals, with a higher frequency during the first 2 h to
capture insulin and BG peak levels {Post-bolus breakfast time
points (min): 0, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65,
70, 80, 90, 120, 150, 180, 210, 240, 300, 330, 360; Post-bolus
lunch time points (min): 0, 10, 20, 30, 40, 50, 60, 70, 80, 90,
120, 180, 240, 300}. Sampling times were based on previous
clinical study experience for bolus microneedle insulin deliv-
ery and had increased sampling frequency in the first 90 min
post-delivery to capture the rapid insulin peaks from
microneedle ID delivery [18, 19]. Blood samples for evening
meal and basal period PK assessment could not be obtained
due to daily blood draw volume limits for patient safety. Se-
rum insulin aspart was measured by a third party laboratory
(IKFE GmbH, Mainz, Germany) using a validated insulin
assay (Invitron ELISA kit). The ELISA kit was not aspart
specific; however, serum insulin concentrations were baseline
corrected by subtracting the calculated mean serum insulin
concentration obtained from measurements at 30, 15, and
0 min before meal intake from all subsequent values. Blood
glucose levels for PD assessments were measured in-clinic
using a standard laboratory method (Super GL Ambulance
glucose analyzer, Freital, Germany).
Study endpoints
The primary PK endpoint was evaluating time and delivery
route (ID vs. SC) effects after a meal bolus excursion on in-
sulin Tmax across the multi-day dosing period, with the study
design powered to this endpoint. Secondary PK endpoints
included maximum plasma insulin concentration (Cmax),
time to 50 % Cmax during insulin onset (T50%max rising)
and offset (T50%max falling), area under the plasma insulin
versus time curve (AUC insulin), and intra- and inter-subject
PK variability. PK endpoints after evening meals and during
basal periods could not be measured due to blood volume
sampling limitations and so were not included for analysis.
PD values were used for subject safety monitoring throughout
the study period; however, the data analysis set comprised
only the 10-h period after the breakfast meal. Postprandial
PD secondary endpoints included area under the BG versus
time curve (AUC BG), absolute BG, change in BG (ΔBG),
maximum BG (BGmax), average BG (BGavg), and change in
BGmax (ΔBGmax). In order to provide a complete picture of
insulin absorption and effect, PK and PD endpoints were eval-
uated at several time points (1, 1.5, 2, 4 h) or time periods (0–
1, 0–1.5, 0–2, and 0–4 h). Device performance and lifetime
was evaluated by monitoring adhesion to treatment site, leak-
age, pump occlusion alarms, and changes in insulin PK data
over time.
Perception and safety
Safety evaluations comprised of recording/classification of
adverse events (including hypoglycemia, BG<60 mg/dL with
or without symptoms), physical examinations, clinical labora-
tory parameters, vital signs, subjective pain assessments, and
assessments of local tissue response at the injection site. Vi-
sual observations of the area around the infusion site for skin
Fig. 2 Timeline and procedures for interventional dosing days, including standardized breakfast and lunch meals with PK/PD sampling, user ratings,
and questionnaire
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irritation, insulin leakage, and any notable abnormalities were
recorded after each bolus delivery. Upon device removal, the
study physician checked the site of insulin administration, as
well as 1 and 2 h later, and scored any local reactions accord-
ing to the Draize erythema and edema scale.
Patients rated bolus-associated pain immediately after in-
sulin delivery for both meals and again each evening at ap-
proximately 6 PM after completion of the morning dosing and
sampling cycles to rate overall discomfort from the infusion
process during the preceding 24 h. The visual analog scale
(VAS) utilized a standard validated 10-cm scale anchored by
Bno pain^ (score 0) and Bsevere pain^ (score 10) without
inclusion of additional numerical or verbal descriptors to
avoid clustering of scores around intermediate points. Scores
were measured as absolute distant from origin. Within 1 h
prior to device removal, patients completed a non-validated
user acceptability questionnaire consisting of a set of standard
multiple choice closed-ended questions covering acceptability
of sensations for infusion sets application and operation, set
satisfaction, willingness to use the respective infusion set
again, and set preference. Responses were restricted to a 5-
point scale generally ranging from extreme agreement/
satisfaction to extreme disagreement/satisfaction depending
upon the question. ID acceptability questions were posed
based on perception alone and within the context of having a
potentially increased glycemic control benefit. These out-
comes were observational in nature, since the study was not
powered for perception and acceptability endpoints.
Statistical analysis
Pharmacokinetic parameters were derived from baseline
corrected blood insulin data. The pharmacokinetic and phar-
macodynamic populations included all patients with data from
either route across 3 days of infusion and patients exposed to
at least one trial product with available data respective of PK/
PD endpoints. PK and PD endpoints were analyzed using a
linear mixed effects model (ANOVA) with sequence, applica-
tion route, meal, and day as factors along with interactions.
The safety population included all patients who had partici-
pated in any trial-related activity after randomization. VAS
pain data comparisons were made between application routes
at each assessment time point using a similar model. Safety
evaluations were summarized by descriptive statistics.
Results
Patients and demographics
In total, 43 patients were screened and 28 (n=15 men, 13
women) were included and randomized to treatment. All pa-
tients were Caucasian. Twenty-three (23) patients completed
the study according to the protocol with five additional partial
or incomplete data sets. Reasons for incompletion included
consent withdrawal (2), insulin delivery failure or pump oc-
clusion alarm during overnight stabilization period (2), and
nausea/emesis adverse event occurrence (1). All 28 patients
exposed to the investigational product were included in the
safety analysis and also constituted the PK/PD analysis set.
Mean (±SD) age was 42.14±9.06 years, weight 75.52±
10.36 kg, BMI 25.05±2.82 kg/m2, and HbA1c 7.16±0.65 %.
Dosing data
ID microneedle boli across all analyzed lunch and dinner de-
liveries (n=156) had a mean (±SD) bolus volume of 6.8±
2.1 U insulin (68±21 µl; range 2.0–12.0 U) and were dose
matched in the SC delivery arm for an individual patient
(Fig. 3a). The insulin pump used in this study delivered boli
rapidly in 1 U increments at approximately 2 s/U for both the
ID and SC routes. Across this small volumetric range of boli
used in the study, any modest differences in dose delivery
timing were ignored during subsequent PK analysis. Basal
insulin delivery rates varied both between patients and within
day for a given patient based on diurnal variability and chang-
ing background insulin need to maintain euglycemia. The ma-
jority of basal rates were between 0.25–1.25 U/h (2.5–12.5 µl/
hour; mean 0.72±0.29 U/h; range 0.1–2.0 U/h) (Fig. 3b), and
during the breakfast and lunch bolus periods, background bas-
al rates remained fixed. Detectable pre-bolus basal insulin
levels were typically near or below the assay detection limits;
however, bolus insulin concentration data was background
adjusted based on the average of the three sequential time
points (−30, −15, 0 min) prior to the breakfast bolus dosing.
Likewise, PK dosing data were analyzed as both non-
normalized concentration data and also dose-normalized for
individual patient mass and dosing volume (data not shown).
Both methods resulted in the same detectable statistical differ-
ences for PK endpoints.
Device performance endpoints
ID delivery throughout the 3-day infusion course was effec-
tive with only one noted device adhesive performance issue of
partial nonadherence and one detectable incidence of leakage.
No other adherence or leakage events for ID or SC devices
were recorded.
PK endpoints
The mean insulin concentration-time profiles across days and
per day across meals both illustrate faster onset and offset of
insulin action for ID delivery with corresponding increased
peak concentrations and are consistent with prior preclinical
and clinical studies [17, 23–27] (Fig. 4, Table 1). The primary
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endpoint of insulin Tmax demonstrated that ID bolus infusion
was associated with a statistically significantly shorter
(p<0.0001) Tmax (Table 1). The 20-min difference in time
to peak concentration represents greater than 40 % reduction
compared to the respective SC delivery. This relative differ-
ence was also maintained across all three treatment days
(Table 1) and both meal types. Similarly, T50_max_rising
and T50_max_falling decreased by ~50 and 25 %, respective-
ly (p<0.0001), not only confirming the increased uptake rate
but also representing faster insulin offset. Due to the faster
uptake, early phase insulin exposure, represented by increased
insulin AUC (ΔAUCIns), was also statistically different (be-
tween the ID and SC routes at early time points (p<0.0001)
and for up to 1.5 h post-bolus). However, these detectable
differences resolved by 2 h (NS difference) indicating a shift
in the concentration-time profile rather than an increase in
total overall insulin bioavailability. Mean overall insulin ex-
posure was routinely lower after the lunch meal owing to
lower carbohydrate content with reduced insulin bolus dosing.
Although time factors for each dosing route and across meal
A B 
Fig. 3 Distribution histogram across all patients (n=28) of a ID bolus
volumes (mean 6.8±2.1; range 2–12 U) and b ID basal rates (mean 0.7±
0.3; range 0.1–2.0 U/h) administered during the 3-day infusion.
Individual patient boli were dose matched in the SC delivery arm. Basal
insulin delivery rates required for euglycemia varied both intra- and inter-
patient based on insulin sensitivity and diurnal variation
A B 
Fig. 4 Serum insulin aspart concentration vs. time PK profiles after
standardized breakfast and lunch meals across all dosing days. a Mean
baseline-adjusted serum insulin concentration (mU/L) by route and b by
treatment day. The data represent mean values (±1SEM) from all 28
patients exposed to trial product
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types were consistent across days, a general trend for increas-
ing maximum insulin concentration (Cmax) and overall
ΔAUCIns was noticed across the 3-day dosing period. This
time effect was significant (p<0.05) for both endpoints when
controlled for route and meal effects but was only between
days 1 and 3. Consecutive days (d1–d2 and d2–d3) were not
statistically distinguishable in insulin concentration effects.
ID intra-subject Tmax variability measured by %CV
was statistically significantly lower vs. SC administration
(30 vs. 37 %, p=0.0128) across meals and days (Table 2),
consistent with previous bolus meal trials. However, inter-
subject variability was not significantly different. Likewise,
intra- and inter-subject variability was not significantly dif-
ferent between the two delivery routes for other PK sec-
ondary endpoints.
PD endpoints
BG vs. time PD profiles indicate ID insulin administration
provides a delay in postprandial rise of glucose levels and
reduction in peak glucose excursions (Fig. 5). Intradermal
microneedle delivery produced a significant reduction in post-
prandial glycemic response for multiple PD factors (BGmax,
ΔBGmax,ΔAUC-BG) up to two hours after meal consump-
tion (Table 3). Mean blood glucose levels for ID delivery were
below SC for both breakfast and lunch meals from ~30–150
and 120 min, respectively. Average blood glucose levels
(BGavg, 0–1 h) were not statistically distinguishable within
the first hour, and this is attributed to the rapid gastric glucose
Table 1 Mean postprandial pharmacokinetic parameters for 3-day ID and SC infusion of insulin aspart across treatment days/meals and for individual
treatment days (n=141–156)
Parameter Route Days 1–3 combined (mean±SD) p value Day 1 Day 2 Day 3
Primary endpoint
Tmax [min] ID 28.5±13.2 <0.0001 27.6±13.9 29.1±13.3 29.1±12.5
SC 47.7±22.8 46.0±28.4 50.1±19.7 47.1±18.3
Secondary endpoints
T50_max_rising [min] ID 6.0±2.4 <0.0001 5.7±2.2 5.8±2.6 6.4±2.3
SC 12.2±7.7 13.2±7.9 12.0±9.5 11.2±5.0
T50_max_falling [min] ID 107±36.1 <0.0001 108±39.2 106±32.6 107±36.7
SC 138±45.1 135±51.1 143±44.1 136±39.5
ΔCmax [mU/L] ID 57.9±46.5 0.0121 54.5±42.1 58.6±47.0 61.2±51.5
SC 48.7±37.6 47.4±37.5 47.2±34.8 51.5±40.8
ΔAUCIns0−1 [mU*h/L] ID 42.5±34.7 <0.0001 39.5±31.4 43.7±36 44.8±37.4
SC 31.3±24 29.9±25.3 30.6±21.1 33.6±25.7
ΔAUCIns0–1.5 [mU*h/L] ID 60.2±51.6 0.0039 56.6±46.4 61.6±54.0 62.8±55.6
SC 49.0±39.0 45.9±38.9 48.7±35.9 52.8±42.5
ΔAUCIns0–2 [mU*h/L] ID 72.5±65.5 NS 68.5±59.0 74.0±67.8 75.7±71.2
SC 62.2±52.3 57.8±50.9 62.6±49.6 66.7±57.0
ΔAUCIns0–4 [mU*h/L] ID 91.0±93.5 NS 86.9±85.8 92.3±94.5 94.4±103
SC 83.4±81.3 77.4±76.2 85.7±82.3 87.7±86.9
Significant difference p<0.05
NS not significant
Table 2 Intra-subject variability (%CV: percentage coefficient of
variation) across all study days and standardized breakfast and lunch
meals
Parameter Time [h] ID %CV SC %CV p value
PK
Tmax [min] 29.6 36.7 0.0128
PD
BG [mg/dL] 1 29.1 20.2 0.0004
1.5 31.5 24.5 0.0069
BGavg [mg/dL] 0–1 26.3 18.2 0.0001
0–1.5 25.6 18.2 <0.0001
0–2 25.9 19.3 0.0003
BGmax [mg/dL] 0–1 25.2 18.1 0.0004
0–1.5 24.5 17.9 0.0001
0–2 23.8 18.5 0.0021
0–4 21.1 18.0 0.0478
ΔBG [mg/dL] 2 90.2 61.4 0.0347
Nonsignificant variability PK/PD endpoints and time periods have been
omitted from table
Fisher’s LSD test; significance indicated by p value <0.05
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absorption and distribution independent of route of insulin
administration since significant decreases were observed for
the BGavg during later time intervals (0–1.5 and 0–2 h). Sig-
nificant differences between ID and SC routes were reported
for BG (at 1 h, 154 versus 165, p=0.0121) andΔBG in the 0–
1 h (p<0.0001) and 0–1.5 h (p=0.0149) time intervals. Intra-
and inter-subject variability was not significantly different be-
tween the two routes for ΔBGmax and ΔAUC-BG. In con-
trast to PK parameters, there were statistical differences of
some glycemic response parameters for ID infusion indicating
slightly higher intra-subject variability (Table 2), whereas the
inter-subject variability was not significantly different be-
tween the two routes.
Safety endpoints
Assessment of infusion site tissue effects was completed using
Draize dermal erythema and edema scoring immediately after
removal of the infusion set on day 3 and for several hours
thereafter. Upon removal, both routes were equivalent with
essentially no detectable erythema or edema. In the subse-
quent 2 h, both routes exhibited an unexpected increase in
both edema and erythema. Erythema severity was similar be-
tween routes, with the majority of sites ≤1, but several in-
stances (4/24 patients) with Draize 2 for ID route. Edema
scores were also predominantly ≤1 for both ID and SC deliv-
ery; however, three scores of Draize 2 and single instances
each of Draize scores 3 and 4 for the ID route were observed
2 h after removal. All sites were reported as normal by the 6 h
time point. Draize scoring was not blinded to the observer and
represented the composite reaction to both the delivery pro-
cess and dermal reaction to medical adhesives and long-term
dressing occlusion. Notwithstanding this, the frequency and
severity of transient dermal effects was modestly elevated for
the ID route.
No clinically relevant changes were observed for clinical
laboratory tests, vital signs, or physical examinations in study
patients. In total, 31 adverse events (AEs) of mild to moderate
severity were reported during the entire study, with none re-
corded as serious. Headache was reported most frequently
with 13 cases in 6 subjects, followed by dizziness (8 cases, 4
subjects), nausea (3 cases, 3 subjects), and vomiting (2 cases,
2 subjects). The other reported AEs were only single occur-
rences. Of these events, 3 were noted as probably, 13 as pos-
sibly, and 15 as unlikely treatment related, and all were re-
solved. There was neither indication of any bias in the number
or type of AEs between treatment route nor evidence of safety
concerns for ID compared to SC delivery.
In total, 123 detected hypoglycemic episodes, defined as
single or consecutive BG measurements below 60 mg/dL,
occurred across the study with the majority being asymptom-
atic. For ID infusion, 67 episodes occurred in 22 subjects, with
56 episodes in 18 subjects after SC infusion. Six hypoglyce-
mic episodes occurred prior to any bolus delivery, and only 11
episodes were associated symptomatic and associated with
other documented AE. All were of mild severity, short dura-
tion (≤1.2 h), and all were resolved, with the majority treated
by oral administration of orange juice/snack. The observed
number of asymptomatic hypoglycemic episodes may have
been influenced by both the intense BG safety monitoring as
well as the tight control exercised in the clinical environment.
Perception endpoints
VAS pain assessments were completed each day at the break-
fast and lunch bolus and after completion of the PK dosing
and sampling cycle. Overall, mean pain scores associated with
A B 
Fig. 5 Blood glucose vs. time PD profiles after standardized breakfast and lunch meals across all dosing days. Mean blood glucose (mg/dL) profile by a
route and b by treatment day. The data represent mean values (±1SEM) from all 28 patients exposed to trial product
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Table 3 Mean±SD pharmacodynamic parameters for all test meals across treatment days and for individual days across meals (n=150–156)
Parameter Route Days 1–3 combined (mean±SD) p value Day 1 Day 2 Day 3
ΔAUC-BG0–1 [mg*h/dL] ID 18.1±21.2 <0.0001 17.2±22.3 18.7±22.0 18.5±19.2
SC 27.5±22.2 29.1±25.7 26.7±20.9 26.5±19.5
ΔAUC-BG0–1.5 [mg*h/dL] ID 36.0±39.8 <0.0001 32.4±41.7 36.8±40.8 39.3±36.8
SC 51.9±42.5 53.4±46.7 50.8±40.9 51.3±39.8
ΔAUC-BG0–2 [mg*h/dL] ID 54.5±60.6 0.0004 47.8±63.1 53.9±61.9 62.8±56.3
SC 75.3±66.5 77.0±73.2 73.6±63.3 75.1±63.0
ΔAUC-BG0–4 [mg*h/dL] ID 126±144 NS 105±148 120±140 156±140
SC 142±155 133±160 140±157 154±148
BG1 [mg/dL] ID 154±49.3 0.0121 151±56.0 155±45.8 156±45.2
SC 165±42.1 158±43.8 169±40.9 170±40.9
BG1.5 [mg/dL] ID 154±51.8 NS 146±52.2 155±51.4 163±51.3
SC 163±49.3 156±51.2 167±48.3 167±48.3
BG2 [mg/dL] ID 154±52.7 NS 145±54.5 152±51.9 165±50.5
SC 160±55.7 152±60.1 164±54.2 164±52.3
BG4 [mg/dL] ID 150±55.9 NS 145±52.1 147±55.5 160±60.1
SC 146±53.7 139±52.4 148±59.4 153±48.9
BGavg0–1 [mg/dL] ID 136±40.5 NS 135±45.9 138±37.4 136±37.3
SC 143±32.2 138±33.4 147±32.5 145±30.3
BGavg0–1.5 [mg/dL] ID 141±40.6 0.0204 137±42.1 144±39.9 143±40.2
SC 150±35.0 144±36.0 154±35.3 152±33.4
BGavg0–2 [mg/dL] ID 144±42.4 0.0375 139±43.8 146±41.9 148±41.8
SC 153±38.0 147±39.3 157±38.2 155±36.1
BGavg0–4 [mg/dL] ID 148±43.6 NS 141±44.0 148±41.3 156±45.0
SC 151±42.0 142±41.2 155±44.0 156±40.1
ΔBGmax0–1 [mg/dL] ID 42.8±30.1 <0.0001 41.3±32.1 43.1±30.2 44.2±28.1
SC 56.7±33.3 57.1±36.0 55.8±31.0 57.2±33.0
ΔBGmax0–1.5 [mg/dL] ID 49.5±34.1 <0.0001 45.0±34.5 49.5±33.5 54.8±34.2
SC 63.6±37.6 65.0±42.3 61.6±33.2 63.9±36.8
ΔBGmax0–2 [mg/dL] ID 53.5±35.2 0.0002 49.4±36.7 52.2±33.7 59.5±34.9
SC 67.8±41.8 69.7±49.0 65.5±34.7 68.1±40.3
ΔBGmax0–4 [mg/dL] ID 67.8±40.8 NS 64.0±43.6 69.4±36.8 70.4±42.2
SC 75.0±45.6 76.5±54.6 72.3±40.0 76.2±40.4
BGmax0–1 [mg/dL] ID 161±46.2 0.0102 159±53.1 162±43.0 162±41.5
SC 172±39.2 166±40.1 176±39.2 175±37.9
BGmax0–1.5 [mg/dL] ID 167±45.8 0.0059 160±46.8 169±45.6 172±45.0
SC 179±41.8 174±43.6 182±41.7 182±40.0
BGmax0–2 [mg/dL] ID 170±46.4 0.0095 165±47.8 171±46.5 176±44.9
SC 183±45.1 178±49.1 186±43.4 186±42.4
BGmax0–4 [mg/dL] ID 184±47.4 NS 178±49.1 186±43.2 188±49.8
SC 188±45.4 179±44.4 193±49.3 194±41.7
ΔBG1 [mg/dL] ID 35.6±35.5 <0.0001 33.3±38.2 35.8±35.4 38.2±32.9
SC 49.8±39.0 49.0±41.5 48.8±37.9 51.8±37.9
ΔBG1.5 [mg/dL] ID 37.2±43.6 0.0149 31.0±44.4 35.8±44.4 45.7±41.2
SC 47.9±48.2 47.5±51.9 47.2±44.8 48.9±48.1
ΔBG2 [mg/dL] ID 36.7±46.5 NS 30.2±48.5 33.1±46.1 48.0±43.3
SC 44.6±55.6 43.7±62.7 44.0±51.2 46.2±52.4
ΔBG4 [mg/dL] ID 33.3±54.9 NS 29.3±54.1 28.0±55.7 43.6±54.8
SC 30.8±52.3 29.7±53.3 27.7±56.8 35.1±47.2
Significant difference p<0.05
NS not significant
340 Drug Deliv. and Transl. Res. (2015) 5:332–345
bolus delivery and perception of the daily infusion process
were low (Fig. 6); however, self-rated pain was statistically
greater for ID compared to SC infusion.
Evaluation of the acceptability and preference question-
naires revealed that the insertion of the infusion set was equal-
ly acceptable for both ID and SC application, with ratings of
100 and 96 % graded as very or extremely acceptable for each
route, respectively. However, acceptability of the infusion set
overall favored the SC route, with 96 % reporting as very or
extremely acceptable versus 83 % for ID (Fig. 7a, b). When
patients were asked about their willingness to use ID infusion
sets again, the majority 61 % responded affirmatively (defi-
nitely or probably responses; 80 % for SC). Interestingly,
when presented with the same question but the potential for
better postprandial glycemic (PPG) control using ID adminis-
tration, this majority increased to 78 % affirmative responses
(Fig. 7c). Similarly, user preference to select between device
types favored SC (54 % responding definitely or most likely
SC vs. 17 % ID; 29 % no difference), but potential PPG
benefit shifted preference selection toward ID over SC
(46 % responding definitely or most likely ID vs. 29 % SC;
25 % no difference) (Fig. 7d).
Discussion
The study is the first clinical investigation of extended dura-
tion intradermal drug infusion using hollowmicroneedle tech-
nology. Numerous others have examined drug delivery from
various microneedle formats, but typically for significantly
shorter durations such as bolus vaccine and drug delivery or
quick dissolving microneedle patches or coatings. The longest
duration microneedle delivery studies have typically involved
evaluating passive preclinical delivery for periods up to 24 h
[28] after transient application of solid microneedle to disrupt
the stratum corneum barrier function. In contrast, this study
has demonstrated continuous active fluid transport through a
single steel microneedle into the dermal tissue over an extend-
ed 3-day period at pharmaceutically relevant insulin delivery
rates. Moreover, the investigational microneedle catheter set
exhibited multiple attributes including mechanical robustness,
the ability to maintain consistency of tissue placement and
engagement, and effective fluid path patency to successfully
maintain glycemia in T1 diabetes patients over the investiga-
tional period. System robustness and efficacy were demon-
strated by the effective BG control obtained, a lack of detect-
able fluid leakage, and effective adhesion throughout the us-
age period. Additionally, the microneedle infusion set was
able to be utilized with commercial insulin pumps originally
designed for subcutaneous infusion therapy, with little to no
deviation from traditional continuous subcutaneous insulin
infusion (CSII) methods. The investigational ID microneedle
set demonstrated functional efficacy equivalent to the current
recommended 3 day usage period for most commercial CSII
set embodiments. This is especially encouraging considering
that many current SC CSII sets fail to meet their expected
usage lifetime [29].
The investigational microneedle infusion set has features
previously described elsewhere [18, 19]. Briefly, the steel
microcannula has external and internal dimensions similar to
microneedles in other material types [30], a proprietary can-
nula tip geometry designed to maximize flow reliability, and
incorporating proprietary hub surface features to maximize
complete insertion. One limitation of the current investiga-
tional ID set is the non-optimized adhesive surface, necessi-















Fig. 6 Mean (± SD) VAS self-
rated pain perception immediately
after bolus insulin delivery for
both meals and for overall daily
infusion after completion of the
morning dosing and sampling
cycles
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adhesion. Although microneedle length dimensions are often
cited as <1 mm, the current 1.5-mm microneedle infusion
set has been clinically vetted to ensure effective dermal locali-
zation and fluid deposition across a range of dosing conditions.
Similar steel microcannula and device designs are found in
commercially available microneedle bolus injection systems
[31]. Other clinical studies have also examined the appropriate-
ness of this length relative to average dermal thicknesses in
both normal subjects and diabetics [32, 33].
In addition to establishing microneedle functional feasi-
bility, the primary study objective was to evaluate the long-
term impact of intradermal delivery route on previously
observed PK time advantages (Tmax) and postprandial gly-
cemic control, including any temporal related changes oc-
curring over the multi-day course of treatment. Recent lit-
erature on CSII using traditional SC sets has demonstrated
the potential for shift in both PK and PD control parame-
ters with time in as little as 3 days [34–36]. Also, little is
known about long-term intradermal delivery kinetics or der-
mal tissue perfusion and absorption since current extended
duration dermal delivery is primarily limited to passive
transdermal patches. A statistically significant shorter Tmax
was demonstrated for mealtime ID bolus infusions, indicating
faster insulin absorption with earlier occurrence of peak serum
insulin concentrations. The faster onset is consistent with PK
results from prior ID microneedle insulin administration stud-
ies. Across days, Tmax was shortened by ~19 min, with time
reductions of ~6 and 31 min for T50%maxrising and
T50%maxfalling, respectively. This was the first demonstrated
use of the intradermal insulin aspart analog, where previous
delivery studies have used the insulin lispro analog. These
results demonstrate the utility of ID microneedle delivery to
speed absorption profiles for multiple insulin types. Future
work to directly compare ID insulin analogs kinetics in a sin-
gle patient cohort could be useful.
For all secondary PK endpoints, the difference between the
ID and the SC route could be statistically demonstrated with
the exception ofΔAUC-INS0-2 and 4 h. With faster ID insu-
lin appearance and disappearance, it was expected that AUC
differences observed during the initial rise are reversible
during the fall and therefore disappear when analyzing the
full excursion. Overall, the analyses of the secondary PK
Fig. 7 User acceptability questionnaire results (n=24) for acceptability
of a infusion set insertion, b set satisfaction, c willingness to use the
respective infusion set again, and d set preference. Some ID
acceptability questions were posed both based on perception alone and
within the context of having an increased postprandial glycemic control
benefit (ID w/PPG)
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endpoints corresponded with the primary endpoint findings
and demonstrated association of ID bolus infusion with
more rapid insulin absorption with higher peak concentra-
tions and faster appearance of insulin in systemic circula-
tion, compared to the respective SC infusion. The cross-day
Tmax consistency for both ID and SC is in contrast to the
above reported CSII examples, where Tmax decreased having
faster absorption by day 3. However, in agreement with those
references, both routes in the current study exhibited the statis-
tically confirmed trend of increasing overall insulin AUC and
Cmax across days. The potential temporal effects on insulin
absorption during continuous infusion remain complex and
require additional study for both the ID and SC routes. A re-
view [29] of the impact of prolonged site exposure to insulin
infusion onmetabolic control cites various contradictory exam-
ples including reported Tmax reductions [36–38], no changes
in PK/PD profiles [39], and average daily BG increases asso-
ciated with increased set wear duration [40, 41]. The limited
and conflicting data on this topic reinforces the need for addi-
tional multi-day PK/PD studies designed to elucidate the un-
derlying mechanisms of these observations.
ID microneedle delivery produced ~7 % less intra-subject
variability, expressed as percentage coefficient variation
(%CV), across meals and days compared to SC administra-
tion. This effect was maintained over all three treatment days,
with no discernable difference in insulin peak onset time for
either the ID or SC study arms. Reductions in insulin absorp-
tion variability are encouraging for patients with intensive
treatment regimens and for development of predictive
closed-loop artificial pancreas (AP) algorithms. The need for
both faster and more consistent insulin kinetics has been cited
as a critical factor for effective development of closed-loop
systems [42, 43].
The postprandial glycemic response, as characterized by
the secondary PD endpoints, was significantly less pro-
nounced after ID bolus administration compared to the respec-
tive SC bolus. In particular during the first 2 h, the increases in
BG-AUC and BG concentrations at different time points were
significantly smaller, and the BG maximum as well as the
average BG level was lower with ID than the SC bolus. Over-
all, the analyses of the pharmacodynamic endpoints demon-
strated better postprandial glycemic control with ID delivery.
A trend of rising blood glucose levels approximately 2 h after
the lunch meal and increasing mean peak blood glucose
values after day 1 was observed for both administration routes.
A review of dosing schedules revealed that additional correc-
tion boli were often required after the lunch meal sampling
period. This may have contributed to the greater increase in
intra-subject variability of some ID glycemic response param-
eters in contrast to previous published observations. A poten-
tial mismatch in the timing of insulin systemic availability and
the gastric glucose absorption rate, especially during the more
slowly absorbed lunch mixed meal, may also have contributed
to this PD variability. In contrast to the day-to-day comparison
of PD outcomes, daily serum insulin profiles and Tmax values
within routes were similar with dailyΔCmax values typically
increasing indicating insulin absorption was not diminished.
Further evaluation is required as many interacting fac-
tors influence metabolic variability such as differences
between injection sites and transient changes insulin
sensitivity [44, 45]. With consistent ID time kinetics, it
may be feasible to optimize both open and closed-loop
prandial insulin infusion to minimize later phase BG
excursions with different meal types.
Clinical safety of ID microneedle insulin delivery was con-
sistent with current practice based on the similar frequency
and type of reported AEs for each route of administration.
Surprisingly, there was no detectable difference in immediate
Draize responses at device removal, even though this would
have been expected after multi-day continuous infusion into
the shallow skin. The delayed onset nature of some observed
Draize scores deserves additional investigation to deconvolute
potential influences beyond the infusion process alone such as
dermal adhesive or insulin reactions.
Overall ID delivery was acceptable per VAS ratings and the
patient questionnaire; however, self-rated pain was higher
with ID bolus infusion. This result was not unexpected since
despite the shorter microneedle length, higher delivery pres-
sures are routinely required for ID bolus delivery due to phys-
ical reduction in needle gauge and increased density of the
dermal tissue bed compared to the SC space. This increased
injection pressure has been demonstrated by ourselves (un-
published data) and others [46] to increase pain perception.
This hypothesis is supported by the acceptability data for basal
and bolus delivery: ID basal was reported as very or extremely
acceptable 96 % of the time (100 % for SC), while ID bolus
delivery was very or extremely acceptable only 57 % of the
time (88 % for SC). The majority of patients found overall ID
microneedle delivery to be acceptable with a willingness to
use again. When presented with the prospect of better glucose
control, willingness to use ID became equivalent to SC, while
preference between sets actually surpassed SC. The challenge
of capturing highly subjective responses, such as pain and
perception, indicates the need for actual usage within the most
clinically relevant context possible. Other mitigating factors
for those observational data must also be considered including
the small sample numbers, lack of powering for perception
endpoints, and additional influences including use of addition-
al adhesive overtaping, the bulky pressure equipment used for
delivery monitoring, and the rapid bolus infusion rate of the
selected insulin pump. Additional repetitive multi-day eval-
uations in a more traditional environment are necessary to
further characterize the impact of continuous ID insulin
infusion on local tissue properties, insulin uptake properties,
user acceptance, and overall safety, as well as any potential
clinical advantages accruing from the observed PK/PD
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changes. Device optimization is also necessary to address
usage and potentially perception factors.
Conclusions
This multi-day study is the longest demonstrated use of ID
hollow microneedle delivery of insulin in patients with
T1DM. Microneedle delivery of the analog insulin aspart
was able to achieve both enhanced pharmacokinetic uptake
and better prandial glycemic control than SC infusion and
maintain these benefits throughout the 3-day testing period.
No severe safety concerns or device performance issues were
observed throughout the course of the study with overall ac-
ceptable device perception and willingness to use among the
participants. Current results indicate ID insulin delivery as a
viable alternative route providing reduced time for insulin
absorption with less intra-subject variability and lower glyce-
mic response and confirming prior clinical findings from
shorter duration infusion. Intradermal delivery continues to
be a potential candidate for both open and closed-loop insulin
delivery systems.
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